Findings from PHRI’s ANNEXA-4 trial were released on Feb. 7, 2019 at the International Stroke Conference in Hawaii, while simultaneously published in the New England Journal of Medicine, in the paper titled “Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa Inhibitors.” Authors include Drs. Stuart Connolly (first author), John Eikelboom and Deb Siegal, investigators at Population Health Research Institute.

“In a single-group trial, 352 patients with acute major bleeding while taking a factor Xa inhibitor were treated with andexanet. Andexanet markedly reduced anti–factor Xa activity, and 82% of the patients had excellent or good hemostatic efficacy at 12 hours,” the NEJM summarizes about ANNEXA-4 findings to date.

Back To Top